FDA drug approval costs have increased significantly over the past ten years, skyrocketing from roughly $30 million per medication in 2015 to more than $50 million in 2025. This only includes ...
For patients with acute ischemic stroke (AIS), tenecteplase (TNK) has improved functional outcome and reduced disability and similar safety to alteplase (tissue plasminogen activator [TPA]), according ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results